Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD19 and anti-CD3 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY